Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News and Views
Nature Biotechnology 26, 1246–1248 (1 November 2008) | doi:10.1038/nbt1108-1246
The many ways to make an iPS cell
&
Abstract
Despite their immense promise, induced pluripotent stem (iPS) cells face several major hurdles on the road to clinical application. One immediate challenge is that current reprogramming methods involve expression of putative oncogenes by retroviral vectors, which may themselves cause cancer by integrating into the genome in a way that disrupts endogenous gene expression.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
